IRIS
BOCCHIA, MONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.309
EU - Europa 20.326
AS - Asia 12.453
SA - Sud America 2.390
AF - Africa 588
OC - Oceania 39
Continente sconosciuto - Info sul continente non disponibili 17
Totale 61.122
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.900
GB - Regno Unito 4.321
RU - Federazione Russa 4.195
CN - Cina 4.098
SG - Singapore 3.861
IT - Italia 3.087
IE - Irlanda 2.602
BR - Brasile 1.974
UA - Ucraina 1.373
VN - Vietnam 1.256
SE - Svezia 1.197
FR - Francia 1.181
DE - Germania 984
HK - Hong Kong 971
FI - Finlandia 650
KR - Corea 631
IN - India 355
BD - Bangladesh 343
ZA - Sudafrica 249
CA - Canada 202
NL - Olanda 172
AR - Argentina 152
IQ - Iraq 131
MX - Messico 122
TR - Turchia 121
JP - Giappone 116
NG - Nigeria 98
PL - Polonia 98
PK - Pakistan 79
ES - Italia 71
BE - Belgio 66
EC - Ecuador 59
ID - Indonesia 54
AT - Austria 53
CZ - Repubblica Ceca 51
MA - Marocco 51
SA - Arabia Saudita 49
UZ - Uzbekistan 49
KE - Kenya 48
VE - Venezuela 48
IR - Iran 42
CO - Colombia 41
EG - Egitto 37
CL - Cile 32
PY - Paraguay 32
AU - Australia 31
CI - Costa d'Avorio 30
PH - Filippine 29
LT - Lituania 28
MY - Malesia 27
AE - Emirati Arabi Uniti 26
PE - Perù 24
TN - Tunisia 23
NP - Nepal 22
AZ - Azerbaigian 21
DO - Repubblica Dominicana 21
DZ - Algeria 21
EE - Estonia 21
CH - Svizzera 19
JO - Giordania 19
GR - Grecia 18
IL - Israele 18
KZ - Kazakistan 18
JM - Giamaica 16
BO - Bolivia 14
LB - Libano 14
OM - Oman 14
HN - Honduras 13
PT - Portogallo 13
BG - Bulgaria 12
SK - Slovacchia (Repubblica Slovacca) 12
UY - Uruguay 12
ET - Etiopia 11
PS - Palestinian Territory 11
RO - Romania 11
LV - Lettonia 10
RS - Serbia 10
TH - Thailandia 10
AL - Albania 9
DK - Danimarca 9
EU - Europa 8
HR - Croazia 8
KG - Kirghizistan 8
KH - Cambogia 8
PA - Panama 8
TT - Trinidad e Tobago 8
HU - Ungheria 7
LK - Sri Lanka 7
BH - Bahrain 6
BY - Bielorussia 6
NZ - Nuova Zelanda 6
QA - Qatar 6
XK - ???statistics.table.value.countryCode.XK??? 6
CR - Costa Rica 5
GE - Georgia 5
LA - Repubblica Popolare Democratica del Laos 5
LU - Lussemburgo 5
MD - Moldavia 5
MN - Mongolia 5
NO - Norvegia 5
Totale 61.046
Salva come PNG Salva come JPEG
Città #
Southend 3.749
Dallas 3.075
Dublin 2.585
Fairfield 2.449
Singapore 2.267
Ashburn 1.987
Chandler 1.311
Houston 1.254
Woodbridge 1.231
Moscow 1.135
Santa Clara 1.134
Jacksonville 1.084
Wilmington 991
Seattle 962
Hong Kong 925
Hefei 884
Beijing 876
San Jose 856
Cambridge 777
Ann Arbor 635
Seoul 625
Siena 536
Princeton 511
The Dalles 450
Nanjing 391
Los Angeles 387
Ho Chi Minh City 371
Lauterbourg 346
Milan 330
New York 316
Helsinki 311
Council Bluffs 286
Hanoi 283
Munich 265
Boardman 249
Florence 226
Johannesburg 215
São Paulo 190
Buffalo 184
San Mateo 173
Rome 158
San Diego 135
Dearborn 125
Dong Ket 122
Nanchang 111
Shanghai 110
Bengaluru 108
London 105
Orem 92
Abuja 90
Redondo Beach 87
Tokyo 80
Shenyang 79
Columbus 78
Hebei 78
Tianjin 78
Nuremberg 74
Chicago 72
Frankfurt am Main 71
Lappeenranta 68
Turku 67
Warsaw 65
Rio de Janeiro 63
Montreal 60
Denver 59
Kunming 59
Baghdad 57
Da Nang 57
Toronto 57
Brussels 55
Chennai 54
Stockholm 54
Düsseldorf 52
Haiphong 52
Izmir 52
Menlo Park 52
Atlanta 51
San Francisco 51
Jiaxing 50
Jinan 50
Turin 50
Guangzhou 49
Changsha 47
Brooklyn 44
Tashkent 44
Phoenix 43
Dhaka 41
Belo Horizonte 39
Amsterdam 38
Naples 38
Norwalk 38
Portsmouth 38
Hangzhou 36
Poplar 36
Bologna 35
Mexico City 35
Zhengzhou 35
Falls Church 34
Washington 34
Curitiba 33
Totale 40.637
Salva come PNG Salva come JPEG
Nome #
VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases 888
null 398
Mycosis Fungoides: a therapeutical review 375
MACOP-B versus F-MACHOP regimen in the treatment of high grade Non-Hodgkin’s Lymphomas 352
A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients 335
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial 334
A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis 334
Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrome 320
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 307
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 303
Circulating CD34+/CD38-/CD26+ Leukemia Stem Cells along Chronic Myeloid Leukemia progression: differences between Chronic, Accelerated and Blast Phase 299
Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis 292
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 291
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 290
Antibody and B-cell responses in myelofibrosis patients after the third doses of mRNA SARS-CoV-2 vaccines 290
A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon 289
Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status? 288
Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia 288
Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia 284
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients 279
A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): A case report 276
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia 276
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia 273
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. 272
Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: Are some patients more sensitive to IV bortezomib? 271
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 270
Atherothrombotic risk assessment during tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients: new insight? 269
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 269
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients 267
Human cytotoxic T lymphocytes form dysfunctional immune synapses with B cells characterized by non-polarized lytic granule release 263
Unravelling the response of chronic lymphocytic leukemia to a novel class of anticancer agents, the pyrrolonaphthoxazepines (PNOXs) 261
Second generation proteasome inhibitors in multiple myeloma 258
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 256
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 255
A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia 251
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients 251
A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2 250
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may explain increased atherothrombotic risk during TKI treatment in chronic myeloid leukemia patients 248
Real word evidence on rituximab utilization: Combining administrative and hospital-pharmacy data 245
Central nervous system multiple myeloma 244
BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial 242
Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy 242
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 240
Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma 238
Lenalidomide and temozolomide combination in a very elderly patient with CNS relapse of diffuse large B-cell lymphoma 236
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients 236
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 236
Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab 235
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia 234
Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination 232
Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients. 231
Peptide vaccines for hematological malignancies: a missed promise? 230
A BRAF Negative Classic Hairy Cell Leukemia Patient in Long Lasting Complete Remission after Rituximab and Pentostatin 230
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 228
A case of acquired factor XIII deficiency secondary to plasmablastic lymphoma 227
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses 224
A solitary uterine relapse in T-cell Acute Lymphoblastic Leukaemia: CT features and pathologic correlation 224
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine 224
Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registry 223
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 223
Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma 220
A fatal unsuspected case of acquired A hemophilia. Misleading role of therapy with acetylsalicylic acid? 220
Transmembrane Transporters hOCT1 and SLCO1B3 Polymorphisms Could Have a Role in Patients Affected By Chronic Myeloid Leukemia Treated with Nilotinib 218
Emerging drugs in chronic myelogenous leukaemia 217
New perspectives for patients with primary CNS lymphoma 216
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 216
Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment 216
Efficacy and safety of eltrombopag during conception and first trimester of pregnancy in a case of refractory severe immune thrombocytopenia 216
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network 215
Variant Philadelphia translocations: Molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA working party on CML analysis 212
Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma 212
FLT3 inhibitors in the management of acute myeloid leukemia 210
A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature 209
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party 209
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib 209
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET 209
Treatment of smoldering multiple myeloma 208
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 208
Antibody response in myelofibrosis patients after three doses of mRNA SARS-CoV-2 vaccine 208
A novel t(6;7)(p24;q21) in a chronic myelocytic leuckemia in complete cytogenetic remission after therapy with imatinib mesylate 207
Daratumumab efficacy in extramedullary orbital myeloma 207
CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland 206
Chronic myeloid leukaemia with extreme thrombocytosis at presentation: Incidence, clinical findings and outcome 206
Primary Nasopharyngeal Hodgkin Lymphoma 205
Development and implementation of the AIDA international registry for patients with Schnitzler's syndrome 204
Anaplastic large cell lymphoma (CD30+/Ki-1+): results of a prospective clinico-pathological study of 69 cases 203
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia 202
First reported case of secondary mixed phenotype acute leukemia after multiple myeloma 202
Apoliprotein E-mediated ferroptosis controls cellular proliferation in chronic lymphocytic leukemia 201
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 201
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia 201
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 201
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 200
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 199
Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol 198
Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes. 197
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia 196
Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas 196
Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia 195
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP 195
Totale 24.966
Salva come PNG Salva come JPEG
Categoria #
all - tutte 194.524
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 194.524
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021440 0 0 0 0 0 0 0 0 0 0 0 440
2021/20223.580 261 434 246 320 150 147 136 138 196 392 410 750
2022/20235.106 324 338 613 695 493 1.005 127 462 519 68 336 126
2023/20244.550 177 116 359 331 170 1.009 1.372 397 62 126 87 344
2024/20259.568 328 498 920 537 1.054 535 290 614 813 483 982 2.514
2025/202621.341 1.767 3.193 2.441 2.592 3.996 910 2.206 635 858 1.464 770 509
Totale 61.995